Regadenoson
Total Payments
$824,025
Transactions
65
Doctors
9
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $824,025 | 65 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $763,054 | 22 | 92.6% |
| Consulting Fee | $54,254 | 6 | 6.6% |
| Travel and Lodging | $6,236 | 29 | 0.8% |
| Food and Beverage | $394.79 | 6 | 0.0% |
| Education | $86.90 | 2 | 0.0% |
Payments by Type
Research
$763,054
22 transactions
General
$60,972
43 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in Heart Failure with Preserved Ejection Fraction | Astellas Pharma Global Development | $149,165 | 0 |
| Characteristics and outcomes of patients selected to undergo pharmacologic myocardial perfusion stress testing using regadenoson-facilitated single-photon emission computerized tomography (SPECT): a retrospective study using a tertiary care database | Astellas Pharma Global Development | $100,000 | 0 |
| The Prognostic Significance of Ischemic Electrocardiographic Changes with Regadenoson Stress Myocardial Perfusion Imaging | Astellas Pharma Global Development | $72,750 | 0 |
| The Prognostic Value of Stress SPECT Myocardial Perfusion Imaging versus Stress Echocardiography | Astellas Pharma Global Development | $66,090 | 0 |
| Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography with a novel 3rd generation dual-source CT system | Astellas Pharma Global Development | $57,532 | 0 |
| Impact of Appropriate Use on the Cost-Effectiveness of SPECT Myocardial Perfusion Imaging in Patients with Known or Suspected Stable Ischemic Heart Disease | Astellas Pharma Global Development | $57,000 | 0 |
| Artifact-Free High-resolution Myocardial Perfusion MRI in Subjects withAbnormal Nuclear Myocardial Perfusion Studies | Astellas Pharma Global Development | $55,347 | 0 |
| Assessment and prognostic significance of global myocardial perfusion reserve (MPR) using coronary sinus flow measurements during Regadenoson stress CMR | Astellas Pharma Global Development | $41,800 | 0 |
| Detection of Coronary Artery Disease in Patients With Atrial Fibrillation Using Regadenoson Stress MRI | Astellas Pharma Global Development | $37,700 | 0 |
| Assessment of Myocardial Flow Reserve (and Effects of Exercise Traiing in Patients with Angina and Negative Coronary Angiograms | Astellas US Technologies | $28,207 | 0 |
| The Simultaneous Assessment of Invasive Fractional Flow Reserve and Myocardial Perfusion by SPECT Using Regadenoson in the Catheterization Laboratory. | Astellas Pharma Global Development | $21,000 | 0 |
| Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve | Astellas Pharma Global Development | $19,895 | 0 |
| Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve | Astellas US Technologies | $11,614 | 0 |
| Stress Cardiac MRI Using Regadenoson for Evaluation of Nonspecific Allograft Dysfunction | Astellas US Technologies | $11,614 | 0 |
| Stress Cardiac MRI Using Regadenoson for Evaluation of Nonspecific Allograft Dysfunction | Astellas Pharma Global Development | $10,244 | 0 |
| Assessment of Myocardial Flow Reserve (and Effects of Exercise Traiing in Patients with Angina and Negative Coronary Angiograms | Astellas Pharma Global Development | $8,717 | 0 |
| Use of Regadenoson for a stress echocardiogram protocol using speckle tracking imaging. | Astellas US Technologies | $6,874 | 0 |
| Tegrated Dual Exercise and Lexiscan PET: IDEAL PET | Astellas Pharma Global Development | $5,716 | 0 |
| A retrospective study of variation in hospital utilization of diagnostic cardiac testing using an acute care hospital database for patients having cardiac biomarker testing and presenting in the emergency room | Astellas Pharma Global Development | $1,039 | 2 |
| THE ROLE OF STRESS MYOCARDIAL PERFUSION IMAGING IN THE CARE OF END STAGE RENAL DISEASE PATIENTS UNDERGOING KIDNEY TRANSPLANT EVALUATION | Astellas Pharma Global Development | $750.00 | 0 |
Top Doctors Receiving Payments for Regadenoson
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charlottesville, VA | $762,015 | 20 |
| , M.D | Cardiovascular Disease | Long Beach, CA | $17,092 | 13 |
| , M.D | Specialist | Chicago, IL | $14,790 | 13 |
| , MD | Nuclear Cardiology | Hawthorne, NY | $14,696 | 10 |
| , MD | Nuclear Medicine | Cleveland, OH | $14,188 | 3 |
| , MD | Internal Medicine | Circleville, OH | $519.44 | 1 |
| , MD | Internal Medicine | Durham, NC | $519.44 | 1 |
| , MD | Cardiovascular Disease | Seattle, WA | $118.63 | 2 |
| , MD | Cardiovascular Disease | Roslyn, NY | $43.45 | 1 |
| Warren Moore | — | Houston, TX | $43.45 | 1 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $719,138
- Astellas US Technologies $58,309
- Astellas Pharma US Inc $46,578
Product Information
- Type Drug
- Total Payments $824,025
- Total Doctors 9
- Transactions 65
About Regadenoson
Regadenoson is a drug associated with $824,025 in payments to 9 healthcare providers, recorded across 65 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2017. In 2017, $824,025 was paid across 65 transactions to 9 doctors.
The most common payment nature for Regadenoson is "Unspecified" ($763,054, 92.6% of total).
Regadenoson is associated with 20 research studies, including "Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in Heart Failure with Preserved Ejection Fraction" ($149,165).